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ABSTRACT
Background: The majority of patients with cholinergic urticaria presents with strong hypersensitivity to autolo-
gous sweat. Patients with severe cholinergic urticaria are frequently resistant to H1 antagonists which are used
in conventional therapies for various types of urticaria. It has been reported that desensitization using partially
purified sweat antigen was effective in a patient with cholinergic urticaria.
Methods: The aim of this study is to determine the usefulness of rapid desensitization with autologous sweat
in severe cholinergic urticaria, because rapid desensitization has proven to be a quick and effective immuno-
therapy for allergies to various allergens. Six patients with severe cholinergic urticaria who are resistant to H1
antagonists and have sweat hypersensitivity were enrolled in a rapid desensitization protocol.
Results: In all six patients, the responses for skin tests with autologous sweat were attenuated after rapid de-
sensitization with autologous sweat. Two of the three cholinergic urticaria patients showed reduced histamine
release with autologous sweat after the rapid desensitization with autologous sweat. Further, the rapid desensi-
tization and subsequent maintenance treatment reduced the symptoms in five of the six patients.
Conclusions: This study provides evidence that rapid desensitization with autologous sweat is beneficial for
treating cholinergic urticaria patients resistant to conventional therapy who have sweat hypersensitivity.
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INTRODUCTION
Cholinergic urticaria, first described by Duke1 in
1924, is characterized by unique clinical features:
pinpoint-sized, highly pruritic wheals with surround-
ing erythema that occur after sweating. Typically, this
disorder occurs in young adults. The precise underly-
ing mechanism(s) of the whealing response in cholin-
ergic urticaria has not yet been clarified but it has
been proposed that sweat hypersensitivity is involved
in the pathogenesis.2-5 Published data suggests that
about two-thirds of cholinergic urticaria patients have
a strong allergy to autologous sweat.2,5 Moreover, it
is conceivable that the antigens in sweat may be au-
tologous proteins, but that has not yet been deter-
mined.4
Although it has been shown that the majority of pa-
tients with cholinergic urticaria respond well to anti-
histamines, some patients with severe cholinergic ur-
ticaria often resist the conventional antihistamine
treatment. Alternative treatments such as scopola-
mine and danazol have been reported, but they are
not generally effective for severe cholinergic urti-
caria. Recently, it was reported that omalizumab, a
humanized monoclonal antibody against IgE, was ef-
fective for a patient with severe cholinergic urticaria,
indicating that cholinergic urticaria is mediated by
IgE.6 Further, desensitization with a partially purified
sweat antigen was effective in a patient with choliner-
gic urticaria.7 Meanwhile, accelerated immunother-
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Table　1　Clinical characteristics of patients with cholinergic urticaria
Patient Age (y) Sex History Accompanying symptom
Total IgE 
(IU/mL)
Skin test 
with serum
Skin test 
with sweat
Period of 
maintenance therapy
1 27 Female Rhinitis, Asthma AD 3403 negative positive 
(1/1000)
2 months
2 25 Female None AD, CU 2163 negative positive 
(1/1000)
12 months
3 45 Female Asthma, AD None 4147 negative positive 
(1/100)
2 months
4 21 Female None None 128 negative positive 
(1/100)
3 months
5 17 Female AD CU 82 negative positive 
(1/100)
5 months
6 32 Female None AD 1131 negative positive 
(1/1000)
2 months
AD, Atopic Dermatitis; CU, Cold Urticaria.
apy build-up schedules in selected patients may pro-
vide a rapid alternative to conventional immunother-
apy without a significant increase in risk.8,9
In this study, we performed rapid desensitization
with autologous sweat in patients with severe cholin-
ergic urticaria who have strong hypersensitivity to
their sweat. Efficacy was evaluated by clinical symp-
toms, intradermal tests with autologous sweat and
histamine release from basophils with autologous
sweat. All patients showed attenuation of skin tests
with autologous sweat after the rapid desensitization.
Two of the three patients with cholinergic urticaria
tested showed reduced histamine release from their
basophils with autologous sweat after the rapid de-
sensitization. Further, the rapid desensitization and
subsequent maintenance therapy attenuated symp-
toms in five of the six patients with cholinergic urti-
caria. This study demonstrates that rapid desensitiza-
tion with autologous sweat can be an effective alterna-
tive therapy for treatment-resistant patients with
cholinergic urticaria who have sweat hypersensitivity.
METHODS
Six female patients with moderate-to-severe choliner-
gic urticaria were enrolled in this study. Cholinergic
urticaria was confirmed by the development of nu-
merous small wheals after exercise until sweating.
The characteristics of those patients are described in
Table 1. Their ages ranged between 17 and 45 years
(mean, 27.8 years). Three of the patients had a past
history of atopic diseases (2 atopic dermatitis [AD], 2
asthma and 1 allergic rhinitis). Four of the patients
were accompanied with cold urticaria or AD. This
study was approved by the Ethics Committee and all
subjects provided written informed consent for this
study. Relevant drugs such as histamine H1-receptor
antagonists were withdrawn for at least 24 hours be-
fore the examination and desensitization therapy.
Venous blood was taken into sterile glass tubes
and sera were separated by centrifugation at 500 g for
20 minutes and were passed through a 0.45-μm
MILLEX HV membrane (Millipore, Molsheim,
France). Sweat was collected from each patient’s fore-
arm after exercise, and was sterilized using a 0.45-μm
MILLEX HV membrane, and then preserved frozen
until use.
Samples of autologous diluted sweat (1100, 1
1000) (0.02 mL), autologous serum (0.05 mL), and
0.9% sterile saline (0.02 or 0.05 mL) were separately
injected intradermally into the volar aspect of the
forearm of each subject. The diameters of wheals and
erythema were measured after 15 minutes. Because
healthy controls occasionally have positive reactions
after intradermal injection of 110 autologous sweat,2
we evaluated patients with strong hypersensitivity to
sweat if the diameters of wheals induced by 1100 or
11000-diluted sweat were equal to or larger than 6
mm. Reactions were assessed as positive if the diame-
ter of the wheal induced by serum was equal to or
larger than 6 mm.
Patients with strong hypersensitivity to sweat were
enrolled in the rapid desensitization protocol. The de-
sensitization protocol involves the following steps.
Two serial autologous sweat dilutions (1100 and 1
1000) in 0.9% sterile saline were prepared. Starting
with an intradermal injection of 0.02 ml diluted au-
tologous sweat at the highest dilution (1100 or 1
1000) that elicited positive reactions in skin tests, the
amount of diluted sweat was increased 50% each time,
from 0.02 ml to 0.2 ml every hour, as detailed in Ta-
ble 2. After these rapid desensitization protocols, we
re-evaluated the hypersensitivity to sweat by intrader-
mal injection (0.02 ml) of the dilution of sweat that in-
itially showed a positive reaction (Table 2). All pa-
tients continued intradermal injections with 0.1 ml of
1100 diluted sweat once per week as maintenance
therapy for several months (patient 1: 2 months, pa-
tient 2: 12 months, patient 3: 2 months, patient 4: 3
months, patient 5: 5 months, patient 6: 2months) (Ta-
ble 1).
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Table　2　Summary of the rapid desensitization protocol
Patients who showed positive reaction for 1/1000 diluted sweat
Step no. Solution dilution Volume
1 1/1000 0.02
2 1/1000 0.03
3 1/1000 0.05
4 1/1000 0.07
5 1/1000 0.1
6 1/1000 0.15
7 1/100 0.02
8 1/100 0.03
9 1/100 0.05
10 1/100 0.07
11 1/100 0.1
12 1/100 0.15
13 1/100 0.2
14 1/1000 0.02
Patients who showed positive reaction for 1/100 diluted sweat
Step no. Solution dilution Volume
1 1/100 0.02
2 1/100 0.03
3 1/100 0.05
4 1/100 0.07
5 1/100 0.1
6 1/100 0.15
7 1/100 0.2
8 1/100 0.02
Histamine release tests were performed in vitro us-
ing HRT (Shionogi, Osaka, Japan) as previously de-
scribed.2 Values of percent histamine release from
basophils of patients with diluted autologous sweat
are shown in Table 3.
The symptom of patients with cholinergic urticaria
was assessed by the patient questionnaire included a
10-point visual analogue scale of urticarial activity be-
fore desensitization and during the maintenance ther-
apy.
RESULTS
All patients had a history of moderate-to-severe
cholinergic urticaria, which was confirmed by the de-
velopment of numerous small wheals after exercise
until sweating. They had positive skin tests to their
own 1100 or 11000 diluted sweat and negative skin
tests to their autologous serum (Table 1). These pa-
tients were assessed as cholinergic urticaria with
strong hypersensitivity to sweat. Because they were
resistant to conventional treatment such as histamine
H1-receptor antagonists, they were enrolled for the
rapid desensitization protocol (Table 2). Rapid desen-
sitization with 11000 and 1100 diluted sweat and
subsequent weekly desensitization with 0.1 ml of 1
100 diluted sweat were performed for patients 1, 2
and 6. Rapid desensitization and subsequent weekly
desensitization with only 1100 diluted sweat were
performed in patients 3, 4 and 5. No patient devel-
oped anaphylaxis or systemic wheal reactions (except
for itching at the injection site) during the rapid de-
sensitization and subsequent maintenance therapy.
Sweat hypersensitivity in these patients was evalu-
ated in vivo by intradermal tests with autologous
sweat and ex vivo by histamine release tests with au-
tologous sweat at pre- and post- rapid desensitization.
In all of them, skin tests with autologous sweat were
attenuated at the post-desensitization compared to
pre-desensitization (Table 3). Two of the three exam-
ined patients showed reduction of histamine release
with autologous sweat after rapid desensitization
compared to before it (Table 3). Moreover, five of the
six patients had improved intensity and frequency of
cholinergic urticaria’s symptom during the rapid de-
sensitization and subsequent maintenance therapy
(Table 3). Only patient 3 discontinued the subse-
quent maintenance therapy because of the lack of effi-
cacy in symptom’s improvement. In particular, patient
4 had gradual but marked improvement in the sever-
ity and frequency of cholinergic urticaria according to
her evaluation (Fig. 1).
DISCUSSION
Cholinergic urticaria can significantly impair quality
of life, especially in relation to exercise, bathing and
sexual activities, although the symptoms subside rap-
idly, usually within 1 hour. Zuberbier et al. suggested
that the majority of patients with cholinergic urticaria
respond well to antihistamines,10 However, patients
with severe cholinergic urticaria are usually resistant
to conventional antihistamines. For patients with se-
vere cholinergic urticaria who resist therapy with H1
antagonists, treatment becomes more difficult. One
study demonstrated the successful use of beta-
blockers, scopolamine, danazol and prednisolone.11
Recently, treatment with a humanized monoclonal
IgG anti-IgE antibody, omalizumab, was shown to be
beneficial for two cases with CU.6,11 However, omali-
zumab has side effects (including anaphylaxis and
headache) and is expensive. In addition, one case
with severe cholinergic urticaria was unresponsive to
omalizumab as well as antihistamines and multiple
other treatments,12 indicating that omalizumab is not
successful for all cases of treatment-resistant cholin-
ergic urticaria.
We previously demonstrated that the majority of
patients with cholinergic urticaria are highly sensitive
to crude autologous sweat.2 In patients with choliner-
gic urticaria and AD, semi-purified sweat antigen was
released from basophils sensitized with their se-
rum.5,13 The incidence of atopic diseases in patients
with cholinergic urticaria tends to be higher in the
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Table　3　Summary of skin tests, histamine release tests (HRT) with sweat and urticarial activity (VAS) in 6 cholinergic urticaria
patients (The comparison between pre-desensitization and post-desensitization)
Skin test (wheal/fl are; mm) %HRT Urticarial Activity (VAS)
Pt before desensitization after desensitization before desensitization
after 
desensitization
before 
desensitization
during maintenance 
therapy
1 8 × 8/9 × 9 (1/1000) 7 × 5/9 × 8 (1/1000) 68.7 (1/1000) 20.4 (1/1000) 10 5
2 × 2/5 × 6 (H) 2 × 3/7 × 4 (H) 50.0 (1/100 IgE) 47.4 (1/100 IgE)
2 6 × 6/9 × 10 (1/1000) 4 × 4/4 × 4 (1/1000) Not Done Not Done 9 4
5 × 5/7 × 7 (H) 6 × 5/14 × 10 (H)
3 6 × 7/12 × 13 (1/100) 4 × 4/7 × 8 (1/100) 33 (1/100) 0 (1/100) 8 discontinuance
4 × 4/8 × 8 (H) 5 × 4/9 × 7 (H) 70.5 (1/10 IgE) 77.6 (1/10 IgE)
4 7 × 7/13 × 14 (1/100) 6 × 6/6 × 6 (1/100) 31 (1/100) 32 (1/100) 10 2
10 × 11/24 × 24 (H) Not done 27.1 (1/100 IgE) 25.4 (1/100 IgE)
5 6 × 6/15 × 8 (1/100) 4 × 4/8 × 6 (1/100) Not Done Not Done 10 4
7 × 5/12 × 8 (H) 5 × 6/10 × 9 (H)
6 8 × 8/9 × 9 (1/1000) 3 × 2/3 × 2 (1/1000) Not Done Not Done 10 3
3 × 4/6 × 10 (H) 4 × 5/7 × 8 (H)
H, histamine prick test; 1/10 or 1/100 IgE, 1/10 or 1/100 diluted anti-IgE antibody.
Fig.　1　The therapeutic effect by a desensitization therapy. 
The rapid desensitization with autologous sweat results in a
gradual but marked improvement in symptoms of cholinergic
uriticaria. (Patient 4: a representative case)
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Japanese population.2,5 These reports suggest that
the possible pathogenesis of cholinergic urticaria as
well as AD is involved in sweat hypersensitivity,
which seems to be mediated via specific IgE for cer-
tain antigens in sweat. Tanaka et al. reported that de-
sensitization with semi-purified sweat antigen is effec-
tive for a patient with cholinergic urticaria.7 More-
over, we found that conventional desensitization with
crude autologous sweat is a safe and beneficial ther-
apy for patients with AD who show hypersensitivity
to sweat. However, the disadvantages of conventional
immunotherapy include poor compliance, delayed ef-
ficacy and patient frustration.9 We therefore used a
rapid desensitization protocol with autologous sweat
for patients with severe cholinergic urticaria who had
hypersensitivity to sweat. The rapid desensitization
therapy and subsequent maintenance therapy were
clinically effective for five of the six patients with
treatment-resistant cholinergic urticaria, and simulta-
neously, the hypersensitivity to sweat was diminished
in most patients.
Our data raise some questions to be resolved in the
future, the most important issue being to characterize
the antigen in sweat. When that antigen is identified,
it could be purified and used to desensitize patients
with cholinergic urticaria. Alternative treatments for
cases that do not respond to desensitization or do not
have a strong hypersensitivity to sweat need to be de-
veloped. We assume that the mechanism of action of
rapid desensitization with sweat involves the attenu-
ation of hypersensitivity to autologous sweat includ-
ing the reduction of reactivity of mast cells but not a
decrease of sweat antigen because autologous sweat
that was used for the desensitization and histamine
release tests had already been collected before the
treatment. However, the detail mechanism of action
of rapid desensitization with sweat should be exam-
ined in the future. Since tolerance may be lost if pa-
tients stop immunotherapy at an early stage, follow-
up studies are required to examine the duration and
frequency of the maintenance therapy.
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